Introduction
The use of chemotherapeutics to treat malignancies is rooted in the use of mustard gas during the World Wars. Sinking of the USS John Harvey carrying a cargo of mustard bombs in the port city of Bari, Italy, in 1943 released the toxic payload and exposed survivors and residents to nitrogen mustard gas. Within 3-4 days, many of those exposed had severe drops in their white blood cell counts. 1 Hypothesizing that the actions of the mustard gas on white blood cells could potentially be used to treat hematologic diseases, several clinicians studied the effectiveness of intravenously administered nitrogen mustards, tris(β-chloroethyl)amine and methyl-bis(β-chloroethyl)amine, and published landmark findings in 1946 that nitrogen mustards were effective in treating various forms of leukemia and lymphoma. 2 Their conclusion heralded in the era of cancer chemotherapeutic discovery:
Chemicals discovered to be therapeutically active in neoplastic disease deserve close study [...] . From this point of view the heuristic aspects of the actions of the β-chloroethylamines here reported may eventually prove of greater importance than the chemical results obtained to date. 2 Cancer is traditionally thought of as unregulated cell replication, where tumor cells acquire mutations allowing them to bypass normal cell cycle checkpoints and apoptosis regulatory pathways. Nitrogen mustards work by alkylating DNA, preventing cell division, and causing cell cycle checkpoint-mediated apoptosis. Many chemotherapeutic agents similarly target cell division. Unfortunately, this mechanism of action is not specific to malignant cells, resulting in chemotherapyrelated toxicities to healthy tissue. The nonspecific effects of most chemotherapeutic agents are the primary limiting factor in the treatment of malignancies. Methods to reduce these toxicities therefore allow for higher dosage regimens of chemotherapeutics and enhance clinical outcomes in many forms of cancer.
The blood-producing hematopoietic system is particularly susceptible to the toxicities of chemotherapeutics given the production demand of approximately 1 trillion blood cells daily. 3 The most abundant white blood cells in the blood are neutrophils, which are essential members of the innate immune system and provide protection from a wide variety of bacterial and fungal pathogens. Given the abundance of neutrophils and their short half-life in the blood of 6-8 hours, the production rate from hematopoietic progenitor cells in the bone marrow is 5×10 10 to 10×10 10 neutrophils per day. 4 The notable amount of cell divisions required to meet this high cellular demand makes the myeloid compartment of the bone marrow hematopoietic system particularly susceptible to chemotherapy.
Chemotherapy-induced neutropenia
Neutropenia is the most serious hematologic toxicity of chemotherapy and often is the limiting factor in dose escalation or duration of chemotherapeutic administration.
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The National Cancer Institute's Common Toxicity Criteria rates the severity of neutropenia into five classifications: Grade 1 is 2.0×10 6 Neutrophils are the primary cellular mediators of the innate immune system and the first line of defense to numerous pathogens. Neutropenic patients are susceptible to infections from the respiratory tract (35%-40% of cases), bloodstream (15%-35%), urinary tract (5%-15%), skin (5%-10%), gastrointestinal tract (5%-10%), and other sites (5%-10%). 7 Many of the symptoms manifested in response to bacterial infection are a consequence of the inflammatory immune response to the pathogen. In neutropenic patients, because they lack neutrophils that are mounting the normal response, they lack many of the normal symptoms of infection and hence it can go unnoticed. Oftentimes, the only clinical sign of infection early on is a fever, which defines a serious clinical outcome of chemotherapy known as "febrile neutropenia", having Grade 4 neutropenia with a fever greater than 38.3°C. More than 60,000 patients are hospitalized annually as a result of neutropenia, and these hospitalizations are estimated to have resulted in $13,400 in medical costs. 8 The average costs for febrile neutropenia encounters were reported to be $22,086, with patients who had febrile neutropenia incurring a mean cost difference of $1,149 per patient, per month. 9 Similarly, another study reported that mean hospitalization costs per patient were $18,042 for patients with neutropenia, $22,839 for patients with neutropenia plus infection or fever, and $27,587 for patients with neutropenia plus infection. 10 Therefore, boosting the bone marrow production of neutrophils is imperative to successful chemotherapy treatment and reduction of medical costs.
The landscape of febrile neutropenia was changed dramatically in the mid-1980s with the molecular cloning of granulocyte colony-stimulating factor (G-CSF).
11-14 Initially believed to be a multipotent hematopoietic growth factor as well an inducer of granulocyte differentiation, G-CSF was found to stimulate proliferation 15, 16 and differentiation 13 of several types of myeloid progenitor cells alone and in combination with other growth factors, [17] [18] [19] and this stimulation of progenitor cells leads to a significant increase in mature neutrophil output. The first clinical trials were performed in cancer patients receiving chemotherapy [20] [21] [22] [23] leading to US Food and Drug Administration approval in 1991 of Neupogen ® (filgrastim). Filgrastim is approved to decrease the incidence of neutropenia in patients with nonmyeloid malignancies receiving chemotherapeutics associated with a significant incidence of severe neutropenia with fever; to reduce incidence and duration of neutropenia in patients with congenital, cyclic, or idiopathic neutropenia; for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia (AML); and to reduce the duration of neutropenia and neutropenia-related clinical sequelae, eg, febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by hematopoietic transplantation.
While successful, the burden and associated pain of daily injections of filgrastim can result in patient discomfort and/ or noncompliance, resulting in missed doses and reduced efficacy. Improved dosage forms that reduce the daily injection requirement can thus lead to enhanced patient care. A longer lasting monomethoxy polyethylene glycol (PEG)-conjugated filgrastim (pegfilgrastim; Neulasta ® ) having the same mechanism of action 24 and clinical effects compared to filgrastim 25 was subsequently introduced, but requires only 
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Lipegfilgrastim in neutropenia single administration per cycle of chemotherapy rather than multiple daily injections of filgrastim. 26 Since the introduction of filgrastim and pegfilgrastim to clinical practice, the management of neutropenia has been enhanced, and several biosimilars have recently entered the marketplace and others are in development (reviewed in Hoggatt and Pelus 27 ).
To date, only a single long-acting biosimilar filgrastim has been introduced. This review will focus on lipegfilgrastim (Lonquex ® ) approved by the European Medicines Agency (EMA) for the treatment of neutropenia.
Lipegfilgrastim
Lipegfilgrastim is a long-acting, site-specific glycol-pegylated r-metHu G-CSF produced by conjugation of a single 20-kDa PEG to the natural O-glycosylation site of G-CSF (threonine 134), using a novel glycoPEGylation technology (Figure 1) . Because the recombinant G-CSF is produced in Escherichia coli, the glycosylation site is empty. Addition of the O-glycan was achieved by enzymatic activity of a truncated N-acetylgalactosaminyltransferase isoform 2 fused with maltose-binding protein at the threonine residue site. A 20-kDa PEG-sialic acid derivative was enzymatically transferred to the O-glycan with a sialyltransferase. In contrast, pegfilgrastim (Neulasta ® ) is a recombinant methionyl human G-CSF with a methoxy-polyethylene glycol propionaldehyde 20-kDa PEG covalently conjugated to its N-terminus. 28, 29 The novel pegylation process used in lipegfilgrastim results in different pharmacokinetic and pharmacodynamic profiles than pegfilgrastim, as discussed later.
In preclinical studies, lipegfilgrastim and pegfilgrastim binding to the G-CSF receptor was evaluated using an NFS-60 cell-based [ 
Pharmacokinetics
Lipegfilgrastim was evaluated in three separate healthy volunteer studies. 30, 31 In a limited healthy volunteer study, three separate subcutaneous injection sites were evaluated; upper arm, abdomen, and the thigh. Bioavailability was found to be lower after injection in the thigh compared to the upper arm or abdomen. However, increases in neutrophil counts were similar across the three injection sites and the recommended administration of lipegfilgrastim is for any of these three sites. 30 In additional clinical studies, lipegfilgrastim was administered as a single subcutaneous injection and in some analyses compared to pegfilgrastim. In the dose escalation phase, administration of lipegfilgrastim was not continued beyond 100 µg/kg as two subjects experienced ANC MAX (maximum absolute neutrophil count) levels greater than 70 neutrophils/nL, the limit for hyperleukocytosis in healthy subjects. 31 The maximal blood concentration was reached after 30-36 hours postadministration. The terminal halflife ranged from approximately 32 to 62 hours, which was 7-10 hours longer for lipegfilgrastim 100 µg/kg compared with pegfilgrastim 100 µg/kg.
Lipegfilgrastim is mainly internalized and eliminated by neutrophils and can be metabolized via intra-or extracellular degradation by proteolytic enzymes, which becomes saturated at higher doses. In vitro data suggest there is little to no effects on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4/5 activity, suggesting lipegfilgrastim does not affect human cytochrome P450 metabolism.
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Safety
In conventional safety and pharmacology studies in animal models, no special hazard for humans was found. In all healthy volunteer studies, the overall safety and tolerability was good, and no serious adverse events were reported. 31 While there have been reports of PEGylation-inducing anti-PEG antibodies in patients, 32, 33 no subject tested positive for antibodies against filgrastim, pegfilgrastim, or lipegfilgrastim demonstrating no significant immunogenicity of the compound. In Phase III trials in breast cancer patients, the safety of lipegfilgrastim was similar to pegfilgrastim. 34, 35 The most commonly reported adverse events in both treatment groups were alopecia, nausea, asthenia, bone pain, diarrhea, fatigue, anorexia, vomiting, headache, and myalgia.
Efficacy
Lipegfilgrastim was compared to pegfilgrastim in two separate clinical trials. The first trial was a randomized, double-blind Phase II study, conducted between June and November of 2008. 35 This study included screening of 229 patients and ultimately enrollment of 208 patients at 37 centers in the Czech Republic, Germany, Hungary, Romania, Russia, and Ukraine. A total of 202 patients (97.1%) completed the study, with three patients withdrawing due to adverse events, two withdrew consent, and one was lost to follow-up. Male and female patients (only three male patients were in the study) 18 years of age with highrisk stage II, III, or IV breast cancer were eligible if they had an Eastern Cooperative Oncology Group performance status 2; absolute neutrophil count 1.5×10 9 /L; platelet count 100×10 9 /L; and adequate cardiac, hepatic, and renal function. Patients had to be chemotherapy-naive and eligible for doxorubicin/docetaxel chemotherapy. Patients received four 3-week chemotherapy cycles and were randomized 1:1:1:1 to receive 3.0-, 4.5-, or 6.0-mg lipegfilgrastim or 6.0-mg pegfilgrastim subcutaneously on chemotherapy day 2. Chemotherapy consisted of doxorubicin 60 mg/m 2 given as an intravenous bolus injection followed 1 hour later by a 1-hour intravenous infusion of docetaxel 75 mg/m 2 . No significant difference in the duration of severe neutropenia for the first chemotherapy cycle among the three lipegfilgrastim doses and pegfilgrastim was observed. The percentage of patients who did not experience severe neutropenia was higher in the 6.0-mg lipegfilgrastim dosage group (62.0%) compared with the 3.0-and 4.5-mg dosage groups (43.4% and 49.0%, respectively). This percentage of patients was also higher than the 6.0-mg pegfilgrastim dosage group (46.3%). For chemotherapy cycles 2-4, the mean duration of severe neutropenia was significantly shorter for the 6.0-mg lipegfilgrastim dosage group versus the pegfilgrastim dosage group. This study established 6.0-mg lipegfilgrastim as the optimal dose for breast cancer patients receiving chemotherapy and established noninferiority to pegfilgrastim in reducing cycle 1 duration of severe neutropenia.
Following this study, a similar experimental approach was taken in a randomized, multicenter Phase III study. 34 Breast cancer patients receiving chemotherapy were randomized 1:1 to receive either the 6.0-mg lipegfilgrastim dose (n=101) or 6.0-mg pegfilgrastim dose (n=101). Lipegfilgrastim was found to be noninferior to pegfilgrastim in the duration of severe neutropenia following cycle 1 of chemotherapy, with a 95% confidence interval of −0.498%, 0.062% days (P=0.1260). Similarly, there was no significant difference in the duration of severe neutropenia between the two groups following cycles 2-4. Intriguingly, the absolute neutrophil count nadir after cycles 2-4 was higher in the lipegfilgrastim group compared to the pegfilgrastim group (2.6 vs 2.0, 2. 
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Lipegfilgrastim in neutropenia vs 2.0, and 2.7 vs 2.3×10 9 /L; P=0.0189, P=0.0353, and P=0.1122, respectively). Similarly, the time to neutrophil recovery was ~1.5 days shorter for the lipegfilgrastim group compared to the pegfilgrastim group (P0.05). The results of this study further demonstrated noninferiority of 6.0-mg lipegfilgrastim compared to 6.0-mg pegfilgrastim and suggest a possible enhancement over pegfilgrastim in neutrophil recovery following chemotherapy.
Recently, the results of a double-blind, randomized, placebo-controlled study in elderly patients with non-smallcell lung cancer receiving cisplatin/etoposide chemotherapy were reported at the 12th Meeting of the International Society of Geriatric Oncology. 36 Patients received 6.0-mg lipegfilgrastim or placebo on day 4 of the chemotherapy cycle, and the incidence of febrile neutropenia was assessed. Fewer elderly patients receiving lipegfilgrastim (0/53; 0.00%) experienced febrile neutropenia compared to the placebo group (4/30; 13.33%) (P=0.0064). There was no significant difference in incidence severity or type of adverse events between the treatment and placebo groups.
Conclusion
Lipegfilgrastim, in the setting of breast cancer chemotherapyinduced neutropenia is at least as equivalent to pegfilgrastim in reducing neutropenic complications. Lipegfilgrastim, Lonquex ® , represents the first long-acting biosimilar filgrastim to reach the market in Germany and has received EMA approval and will likely be marketed throughout Europe.
As the Neupogen ® and Neulasta ® patent lives have ended, and given the large economic market of G-CSF therapies in reducing the complications associated with chemotherapy, there has been a large effort in biosimilar development. To date, several filgrastim biosimilars have received US Food and Drug Administration and/or EMA approval and have entered the marketplace (recently reviewed in Hoggatt and Pelus 27 ). While lipegfilgrastim is the first long-acting biosimilar filgrastim to reach the market, additional long-acting biosimilars, some with unique modifications to increase half-life, are currently in late-stage clinical development (reviewed in Hoggatt and Pelus 27 ). To date, no long-acting biosimilar filgrastim has been approved by the US Food and Drug Administration. Additionally, dosage forms that eliminate the need for injection altogether, such as the topical filgrastim product Nupen, may enhance patient compliance and resulting care in some clinical applications, although further clinical studies are required.
Overall, the use of biosimilar filgrastim and pegfilgrastim products will be dictated by market prices and individual center preferences until further enhancements in efficacy or ease of administration, eg, oral, are identified and developed. In the shorter term, it is expected that biosimilar G-CSF agonists may reduce the significant medical costs of neutropenia treatment and facilitate market expansion.
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